{"downloaded": true, "htmlmade": false, "full": {"id": "29480231", "source": "MED", "pmid": "29480231", "pmcid": "PMC5842785", "fullTextIdList": {"fullTextId": "PMC5842785"}, "doi": "10.3233/jpd-171285", "title": "Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease.", "authorString": "K\u00f6nig A, Vicente Miranda H, Outeiro TF.", "authorList": {"author": [{"fullName": "K\u00f6nig A", "firstName": "Annekatrin", "lastName": "K\u00f6nig", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany."}}}, {"fullName": "Vicente Miranda H", "firstName": "Hugo", "lastName": "Vicente Miranda", "initials": "H", "authorId": {"@type": "ORCID", "#text": "0000-0001-8065-9259"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "CEDOC, Chronic Diseases Research Center, NOVA Medical School, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Campo dos M\u00e1rtires da P\u00e1tria, Lisboa, Portugal."}}}, {"fullName": "Outeiro TF", "firstName": "Tiago Fleming", "lastName": "Outeiro", "initials": "TF", "authorId": {"@type": "ORCID", "#text": "0000-0003-1679-1727"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany."}, {"affiliation": "CEDOC, Chronic Diseases Research Center, NOVA Medical School, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Campo dos M\u00e1rtires da P\u00e1tria, Lisboa, Portugal."}, {"affiliation": "Max Planck Institute for Experimental Medicine, G\u00f6ttingen, Germany."}, {"affiliation": "Institute of Neuroscience, The Medical School, Newcastle University, Framlington Place, Newcastle Upon Tyne, UK."}]}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-8065-9259"}, {"@type": "ORCID", "#text": "0000-0003-1679-1727"}]}, "dataLinksTagsList": {"dataLinkstag": "altmetrics"}, "journalInfo": {"issue": "1", "volume": "8", "journalIssueId": "2654503", "dateOfPublication": "2018", "monthOfPublication": "0", "yearOfPublication": "2018", "printPublicationDate": "2018-01-01", "journal": {"title": "Journal of Parkinson's disease", "ISOAbbreviation": "J Parkinsons Dis", "medlineAbbreviation": "J Parkinsons Dis", "NLMid": "101567362", "ISSN": "1877-7171", "ESSN": "1877-718X"}}, "pubYear": "2018", "pageInfo": "33-43", "abstractText": "Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.", "affiliation": "Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Research Support, Non-U.S. Gov't", "review-article", "Review", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Parkinson Disease", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Diabetes Complications", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PC", "qualifierName": "prevention & control", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Pyruvaldehyde", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Glucose", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Hypoglycemic Agents", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Risk Factors"}, {"majorTopic_YN": "N", "descriptorName": "Protein Processing, Post-Translational", "meshQualifierList": {"meshQualifier": {"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Glycosylation", "meshQualifierList": {"meshQualifier": {"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Homeostasis"}, {"majorTopic_YN": "N", "descriptorName": "Maillard Reaction", "meshQualifierList": {"meshQualifier": {"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "alpha-Synuclein", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Glycation End Products, Advanced", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}}}]}, "keywordList": {"keyword": ["Glycation", "alpha-Synuclein", "Parkinson\u2019s Disease", "Maillard-reaction"]}, "chemicalList": {"chemical": [{"name": "Hypoglycemic Agents", "registryNumber": "0"}, {"name": "alpha-Synuclein", "registryNumber": "0"}, {"name": "Glucose", "registryNumber": "IY9XDZ35W2"}, {"name": "Pyruvaldehyde", "registryNumber": "722KLD7415"}, {"name": "Glycation End Products, Advanced", "registryNumber": "0"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.3233/JPD-171285"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5842785"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5842785?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "7", "hasData": "N", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by-nc", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2019-10-29", "dateOfCreation": "2018-02-27", "firstIndexDate": "2018-02-26", "fullTextReceivedDate": "2020-07-12", "dateOfRevision": "2019-10-29", "firstPublicationDate": "2018-01-01"}, "htmllinks": "https://europepmc.org/articles/PMC5842785", "abstract": "Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.", "Keywords": ["Glycation", "alpha-Synuclein", "Parkinson\u2019s Disease", "Maillard-reaction"], "pdflinks": "https://europepmc.org/articles/PMC5842785?pdf=render", "journaltitle": "Journal of Parkinson's disease", "authorinfo": ["K\u00f6nig A", "Vicente Miranda H", "Outeiro TF"], "title": "Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease."}